A Phase 4 interventional study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC) in HIV-1-infection, sponsored by The Crofoot Research Center, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-26.
Sponsored by The Crofoot Research Center, Inc. · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to demonstrate the effectiveness of Symtuza® in a rapid reinitiation model of care in patients with HIV-1 infection and who are treatment-experienced but have been off of antiretroviral therapy (ART) for 12 or more weeks.
In the United States, only 49 percent of persons living with HIV infection are currently retained in care (Centers for Disease Control, 2018). Many individuals initially start antiretroviral therapy (ART) but fall out of care and discontinue treatment, only to reenter care at a later date. Gaps in care contribute to the likelihood that a patient might not have a recent viral load or CD4 count, as well as knowledge of previous ART regimens or resistance data. Furthermore, high plasma HIV-1 RNA is a major risk factor for HIV transmission, and effective ART can reduce viremia and transmission of HIV to sexual partners by more than 96% (Cohen et al., 2011; Palella et al., 1998). Thus, a secondary goal of ART is to reduce the risk of HIV transmission.
Traditional models of care have an initial period where a person is brought back into care and assessed by a healthcare provider on various factors, including HIV RNA level, genotypic/ phenotypic resistance, immune status, renal/hepatic function, and general medical comorbidities before reinitiating ART. These steps can add weeks without treatment and, in turn, delay resupression of the virus and immune system improvement, as well as continuing to contribute to the community viral load and offering more opportunities for the person to fall out of care again. (Horburg et al., 2013) This traditional model places a burden on both the patient and the healthcare system as multiple visits are required, each one a potential point where the patient can be lost again to follow-up.
A rapid reinitiation of ART for persons who have fallen out of care is a potential intervention that could improve retention rates, patient satisfaction, and clinical outcomes. Given these factors, the single-tablet regimen of D/C/F/TAF (Symtuza®) may serve as an ideal regimen for a Rapid Reinitiation model of care, combining potency, sustained efficacy, a high genetic barrier to resistance, with a well-described safety profile of the individual components, and practical, convenient dosing.
This prospective, multicenter study will follow subjects for 48 weeks with subjects either returning to the site or having a virtual visit (TeleVisit) for Weeks 2, 4, 12, 24, 36, and 48. Baseline safety labs will dictate whether the ART regimen will need to be modified but will not be required to be completed at the initiation of ART. Assessment of drug accountability, reasons for non-adherence, recording of concomitant therapies, adverse events, weight, physical examinations (complete or symptom-directed), laboratory evaluations (for efficacy and safety), and health outcome assessments will be performed from baseline onwards.
3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.
This study's enrollment of 75 is below the median of 96 across 2,253 interventional studies indexed under Acquired Immunodeficiency Syndrome.
Browse Acquired Immunodeficiency Syndrome studies →This is the only study on the registry with The Crofoot Research Center, Inc. as lead sponsor.
Compared within Acquired Immunodeficiency Syndrome, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive oral tablet containing Darunavir 800 milligram (mg)/ Cobicistat 150 mg/ Emtricitabine 200 mg/ Tenofovir Alafenamide 10 mg (D/C/F/TAF) fixed-dose combination (FDC) once daily within 24 hours of the screening/baseline visit.
Drug: Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC)
Drug pages: Darunavir · Cobicistat · Emtricitabine · Tenofovir alafenamide
Participants will receive Symtuza®. An oral tablet containing Darunavir 800 mg /Cobicistat 150 mg /Emtricitabine 200 mg /Tenofovir Alafenamide 10 mg FDC, once daily within 24 hours of the screening/ baseline visit.
The proportion of subjects who have HIV-1 RNA <50 copies/mL at week 48
The proportion of subjects who have HIV-1 RNA \<50 copies/mL at week 48 as defined by the FDA snapshot analysis (ITT)
Time frame: 48 week
Proportion of subjects who have HIV-1 RNA <50 copies/mL at week 48
Proportion of subjects who have HIV-1 RNA \<200 copies/mL at week 48 as defined by the per-protocol (PP) analysis set
Time frame: Week 48
Proportion of subjects who have HIV-1 RNA <50 copies/mL at week 48
Proportion of subjects who have HIV-1 RNA \<200 copies/mL at week 48 as defined by the FDA snapshot analysis (ITT)
Time frame: Week 48
Proportion of subjects who have HIV-1 RNA <200 copies/mL at week 24
Proportion of subjects who have HIV-1 RNA \<200 copies/mL at week 24 as defined by the FDA snapshot analysis (ITT)
Time frame: Week 24
Change from baseline in HIV-1 RNA viral load
Change from baseline in log10 HIV-1 RNA viral load at Weeks 24 and 48
Time frame: Weeks 24 and 48
Change in baseline CD4 cell count
Change in baseline CD4 cell count at Weeks 12, 24, and 48
Time frame: Weeks 12, 24, and 48
Discontinuation after enrollment based on study stopping rules
Proportion of subjects that required discontinuation after enrollment based on study stopping rules
Time frame: Week 48
Discontinuation due to adverse events
Proportion of subjects discontinuing therapy due to adverse events
Time frame: Week 48
Proportion of subjects experiencing grade 3 and 4 adverse events
Proportion of subjects experiencing grade 3 and 4 adverse events
Time frame: Week 48
Proportion of subjects experiencing serious adverse events
Proportion of subjects experiencing serious adverse events
Time frame: Week 48
Proportion of subjects experiencing grade 3 and 4 laboratory abnormalities
Proportion of subjects experiencing grade 3 and 4 laboratory abnormalities
Time frame: Week 48
Proportion of subjects meeting resistance stopping rules requiring discontinuation of study drugs due baseline resistance findings
Proportion of subjects meeting resistance stopping rules requiring discontinuation of study drugs due baseline resistance findings
Time frame: Week 48
Proportion of subjects with baseline RT, INI, and PR (primary and secondary) RAMs
Proportion of subjects with baseline RT, INI, and PR (primary and secondary) RAMs
Time frame: Week 48
Proportion of subjects developing RAMs and loss of phenotypic susceptibility, when available, upon meeting PDVF
Proportion of subjects developing RAMs and loss of phenotypic susceptibility, when available, upon meeting PDVF
Time frame: Week 48
Proportion of subjects with PDVF at Week 24 and Week 48
Proportion of subjects with PDVF at Week 24 and Week 48
Time frame: Weeks 24 and 48
Proportion of subjects lost to follow-up throughout the 48 Weeks of treatment
Proportion of subjects lost to follow-up throughout the 48 Weeks of treatment
Time frame: Week 48
Proportion of subjects taking study drug at Week 48 who have a documented clinic visit with a healthcare provider within 90 days of Week 48 visit.
Proportion of subjects taking study drug at Week 48 who have a documented clinic visit with a healthcare provider within 90 days of Week 48 visit.
Time frame: Week 48
Mean total satisfaction scores on the HIVTSQs at Weeks 4, 24, and 48
Mean total satisfaction scores on the HIVTSQs at Weeks 4, 24, and 48
Time frame: Weeks 4, 24, and 48
Mean total depression scores on the PHQ-9 at baseline and Weeks 4, 24, and 48
Mean total depression scores on the PHQ-9 at baseline and Weeks 4, 24, and 48
Time frame: Weeks 4, 24, and 48
Adherence as measured by pill count at Weeks 4, 12, 24, and 48
Adherence as measured by pill count at Weeks 4, 12, 24, and 48
Time frame: Weeks 4, 12, 24, and 48
Plan to share: No
Ran from Sep 2021 to primary completion in Apr 2024, 31 months.
Of 70 phase 4 interventional studies under Acquired Immunodeficiency Syndrome, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 47. This study's 31 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Darunavir · Cobicistat · Emtricitabine · Tenofovir alafenamide
Acquired Immunodeficiency Syndrome →